ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2118

New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry

Robert Spandorfer1, Kevin Kane2, George Reed2, Dimitrios Pappas2, Joel Kremer2, Jeffrey Curtis3 and Iris Navarro-Millán4, 1Hospital for Special Surgery, Brooklyn, NY, 2CorEvitas, LLC, Waltham, MA, 3University of Alabama at Birmingham, Birmingham, AL, 4Weill Cornell Medicine, Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, Disability, registry, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated with disability among patients with RA. There is insufficient data however on disease activity and duration in this population, and the impact of new-onset disability is unknown. We need to understand these factors to develop sufficient preventive measures for patients with RA and disability. We hypothesize that among patients with RA younger than 65 years of age, new-onset disability is associated with a higher risk for CVD, and the primary contributing factors include traditional risk factors, disease characteristics, and medications.

Methods: This retrospective cohort study using the CorEvitas RA registry included patients age < 65 years who were working as of registry enrollment and had no history of CVD (MI, CAD, CVA, TIA, or PAD). The exposure was new-onset disability defined as a change from working to disabled while < 65 years or to retired while < 60 years. The comparator group was patients consistently working who were age- and sex-matched in a 4:1 ratio to the newly disabled. Demographics, comorbidities, RA-specific variables, and medications at baseline (time of onset of disability or enrollment for matched controls) were analyzed using descriptive statistics. Incidence rates of CVD for each group were calculated using Poisson regression. We built sequential Cox proportional hazards models with age as the time axis to identify the factors that best explained the excess CVD risk associated with disability among patients with RA. We selected covariates based on the association with CV risk or new-onset disability in the univariate analysis.One set of models used all factors at baseline; a second set allowed for time-varying covariates.

Results: 8370 patients were included (1674 in the disabled group and 6696 in the working group) with an overall mean age of 53 years and 80.7% female (Table 1). Mean follow-up was 10 years. Almost half (46%) of the disabled group reported depression compared to 9.14% in the working group (p < 0.001). The age and sex-adjusted incidence rate of CV events was 5.40 (95% CI 3.88, 7.52) events per 1000 person-years in the disabled group and 2.17 (95% CI 1.68, 2.80) in the non-disabled group (p < 0.001). The hazard ratio (HR) for CVD associated with disability was 2.32 (95% CI 1.52, 3.53) in the age- and sex-adjusted model, 1.78 (95% CI 1.09, 2.91) in the fixed covariate model, and 1.86 (95% CI 1.12, 3.08) in the time-varying model (Table 2). No model fully explained the excess risk for CVD in the disabled population as a significant association persisted despite multivariate adjustment.

Conclusion: Patients younger than 65 with RA who experience new-onset disability are at significantly higher risk for CVD compared to age- and sex-matched non-disabled patients with RA. This excess risk is partially explained by traditional risk factors, reduced physical function, and medications, but much of the risk remains unexplained. This is likely due to unmeasured variables, such as social determinants of health and related health behaviors. We thus need to examine how a holistic approach in patient care may mitigate this excess CVD risk in RA patients with disability.

Supporting image 1

Table 1. Baseline characteristics of patients with rheumatoid arthritis younger than age 65, overall and by disability status*.

Supporting image 2

Table 2. Hazard ratio (HR) for cardiovascular disease event among RA patients with and without disability. Univariate and multivariable-adjusted Cox proportional hazards models with fixed and time-varying covariates shown.


Disclosures: R. Spandorfer: None; K. Kane: None; G. Reed: CorEvitas, LLC, 2, Corrona Research Foundation, 2; D. Pappas: AbbVie, 2, 6, CorEvitas, LLC, 3, 8, 11, Corrona Research Foundation, 4, Novartis, 6, Roche Hellas, 2, 6, Sanofi, 1, 6; J. Kremer: CorEvitas, 2, 8; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb, 2, 5, CorEvitas, 2, 5, Eli Lilly and Company, 2, 5, Janssen, 2, 5, Myriad, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5; I. Navarro-Millán: None.

To cite this abstract in AMA style:

Spandorfer R, Kane K, Reed G, Pappas D, Kremer J, Curtis J, Navarro-Millán I. New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/new-onset-disability-in-rheumatoid-arthritis-is-an-underrecognized-cardiovascular-risk-factor-a-retrospective-cohort-study-using-the-corevitas-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-onset-disability-in-rheumatoid-arthritis-is-an-underrecognized-cardiovascular-risk-factor-a-retrospective-cohort-study-using-the-corevitas-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology